Quick Answer
Immunovant, Inc. reported Net Income of -$413.84 million for fiscal year 2025.
Immunovant, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$413.84M -59.6% |
-$259.34M -22.9% |
-$210.96M -34.6% |
-$156.73M -45.9% |
-$107.43M -61.8% |
-$66.39M -132.1% |
| Diluted EPS | -$2.73 -45.2% |
-$1.88 -9.9% |
-$1.71 -19.6% |
-$1.43 -17.2% |
-$1.22 | — |
| Total Assets | $776.22M +16.5% |
$666.37M +64.2% |
$405.84M -21.3% |
$515.56M +25.0% |
$412.49M +277.1% |
$109.39M +691.1% |
| Cash and Equivalents | $713.97M +12.4% |
$635.37M +68.7% |
$376.53M -23.8% |
$493.82M +23.4% |
$400.15M +297.9% |
$100.57M +1339.8% |
| Stockholders Equity | $707.45M +14.5% |
$617.76M +70.4% |
$362.49M -22.8% |
$469.82M +20.0% |
$391.48M +316.2% |
$94.07M +1181.8% |
| R&D Expense | — | — | — | $101.81M +48.4% |
$68.60M +43.1% |
$47.93M +86.2% |
| Shares Outstanding | 170.11M +16.8% |
145.58M +11.7% |
130.33M +11.9% |
116.48M +18.9% |
97.97M +79.3% |
54.66M +41.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | December 31, 2025 | -$110.64M | +0.4% | +12.5% |
| Diluted EPS | December 31, 2025 | -$0.61 | +19.7% | +16.4% |
| Total Assets | December 31, 2025 | $1.05B | +150.0% | +80.5% |
| Cash and Equivalents | December 31, 2025 | $994.52M | +165.4% | +90.6% |
| Stockholders Equity | December 31, 2025 | $986.13M | +179.7% | +89.7% |
| R&D Expense | September 30, 2022 | $37.74M | +76.7% | +32.7% |
| Operating Income | September 30, 2019 | -$419.8K | — | -354.6% |
| Shares Outstanding | December 31, 2025 | 203.32M | +38.1% | +16.5% |
- Immunovant, Inc. reported Net Income of -$413.84 million for fiscal year 2025.
- Immunovant, Inc. showed a decrease of -59.6% in Net Income compared to the prior fiscal year.
- Immunovant, Inc. reported Diluted EPS of $2.73 per share (loss) for fiscal year 2025.
- Immunovant, Inc. showed a decrease of -45.2% in Diluted EPS compared to the prior fiscal year.
- Immunovant, Inc. reported Total Assets of $776.22 million for fiscal year 2025.
- Immunovant, Inc. showed an increase of +16.5% in Total Assets compared to the prior fiscal year.
- Immunovant, Inc. reported Cash and Equivalents of $713.97 million for fiscal year 2025.
- Immunovant, Inc. showed an increase of +12.4% in Cash and Equivalents compared to the prior fiscal year.
- Immunovant, Inc. reported Stockholders Equity of $707.45 million for fiscal year 2025.
- Immunovant, Inc. showed an increase of +14.5% in Stockholders Equity compared to the prior fiscal year.
- Immunovant, Inc. reported R&D Expense of $101.81 million for fiscal year 2022.
- Immunovant, Inc. showed an increase of +48.4% in R&D Expense compared to the prior fiscal year.
- Immunovant, Inc. reported Shares Outstanding of 170.11 million shares for fiscal year 2025.
- Immunovant, Inc. showed an increase of +16.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: